

Case 1
Intervention- 0.09ml stem cell+0.01ml triamcinolone

Investigations	Baseline	Day 4-7	2 week	4 week	8 week	12 week	24 week	1 year
BCVA (Snellen acuity)	1/60	6/60	6/36	6/60	6/36	6/9	6/12	6/9
IOP (mm of Hg)	14	16	16	18	16	16	14	16
Evidence of intraocular inflammation	no	AC- 2+ cells RL cells+	AC-No cells RL cells+	AC- No cells RL cells+	AC-No cells RL cells+	AC-No cells RL-no cells	AC-no cells RL-no cells	AC- no cells RL- no cells
Anterior segment	No NVI	No NVI	No NVI	No NVI	No NVI	No NVI	No NVI	No NVI
Anterior segment FA				No leak				
Gonioscopy for NVA				No NVA	No NVA	No NVA	No NVA	No NVA
CMT (in microns)	764	513	522	653	601	250	262	242
ERG	RE a-34μV 54mS b-43.4μV 1/08mS LE a-34μV 62mS b-41.3μV 118mS			RE a-56μV 60mS b-79μV 146mS LE a- 52μV 68mS b- 63μV 146mS			RE a-37μV 23mS b-58μV 38mS LE a-43μV 24mS b-77μV 40mS	

BCVA- Best corrected visual acuity; IOP- Intraocular pressure; FA- Fluorescein angiography; CMT- Central macular thickness, NVI- Neovascularization of iris; NVA- Neovascularization of angle; ERG- Electro retinogram
AC- Anterior segment; RL cells- Retro lental cells

Case 2

Intervention: 0.09ml stem cell+ 0.01ml Triamcinolone

Investigations	Baseline	Day 4-7	2 week	4 week	8 week	12 week	24 week	1 year
BCVA (Snellen acuity)	3/60	FCCF	1/60	2/60	2/60	Missed follow up	6/60	6/60
IOP (mm of Hg)	12	21	14	14	10		16	18
Evidence of intraocular inflammation	no	Central vitreous haze AC-0.5+ cells	Central vitreous haze	Central haze	No AC cells		No AC cells	No AC cells
Anterior segment	No NVI	No NVI	No NVI	No NVI	No NVI		No NVI	No NVI
Anterior segment FA				No NVI				
Gonioscopy for NVA				No NVA	No NVA		No NVA	No NVA
CMT (in microns)	ERM+	Media haze	Media haze	333 ERM +	448 ERM +		Pseudo hole with ERM	Pseudo hole with ERM

BCVA- Best corrected visual acuity; IOP- Intraocular pressure; FA- Fluorescein angiography; CMT- Central macular thickness, NVI- Neovascularization of iris; NVA- Neovascularization of angle; ERG- Electro retinogram
AC- Anterior chamber; FCCF- Finger counting close to face; ERM- Epiretinal membrane

Case 3

6 week follow up -NVA with NVG .Pan retinal photocoagulation done.

7 week follow up -Intracameral bevacizumab followed by Trabeculectomy with mitomycin-c

14 months after sham injection-Phacoemulsification with IOL implantation. BCVA- 1/60 on 7th post operative day

Investigations	Baseline	Day 4-7	2 week	4 week	6 week (Presented with NVG)	12 week	24 week
BCVA (Snellen acuity)	FC1/2m	FC1/2m	FC1/2m	Missed follow up	FC1/2m	FCCF	FCCF
IOP (mm of Hg)	16	14	16		32	14	16
Evidence of intraocular inflammation	No	No	No		No	AC-1+ cells	No
Anterior segment CP	No NVI	No NVI	No NVI		No NVI	No NVI	No NVI
Anterior segment FA							
Gonioscopy for NVA			No NVA		NVA+	Regressed NVA	Regressed NVA
CMT (in microns)	1151	1021	556		348 VMT with ERM	Poor image	Poor image

BCVA- Best corrected visual acuity; IOP- Intraocular pressure; FA- Fluorescein angiography; CMT- Central macular thickness, NVI- Neovascularization of iris; NVA- Neovascularization of angle; ERG- Electro retinogram AC- Anterior chamber; FCCF- Finger counting close to face; ERM- Epiretinal membrane; VMT- Vitreo macular traction; FC 1/2m- Finger counting at ½ metre; NVG- Neovascular glaucoma.